Pilot Study of Fostamatinib Disodium/R935788 for the Treatment of Adult Refractory Immune Thrombocytopenic Purpura (ITP)
Part of paid clinical trials in New York, New York.
- Sponsor
- Rigel Pharmaceuticals
- Study ID
- NCT00706342
- Phase
- PHASE2
- Status
- Completed
Conditions
- Purpura, Thrombocytopenic, Idiopathic
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 75 Years
- Healthy Volunteers
- Not accepted
Interventions
- Fostamatinib Disodium / R935788 — DRUGR935788 tablets
Study Details
The purpose of this study is to determine whether Fostamatinib Disodium is safe and effective in the treatment of Adult Refractory Immune Thrombocytopenic Purpura (ITP).
Key Dates
- Start date
- Jan 31, 2007
- Status verified
- May 2016
- Primary completion
- Apr 30, 2010
- Completion
- Apr 30, 2010
Study Design
- Enrollment
- 18 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: 1
Primary Outcome Measure
Summary of Patients Whose Platelet Count Increased by at Least 20,000/mm3 From Baseline to a Total of 30,000/mm3 or More - Week 2 [ Time Frame: 2 weeks ]
Locations (2)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Research Site | New York | New York | 10065 | - |
| Research Site | Cleveland | Ohio | 44195 | - |
Find similar trials in New York, NY
By research site